

附件一

<https://www.sgo.org/clinical-practice/guidelines/new-figo-ovarian-cancer-staging-guidelines/>

## **New FIGO ovarian cancer staging guidelines**

**January 2014**

The International Federation of Gynecologists and Obstetricians (FIGO) has revised the staging of ovarian cancer. The approved, new ovarian cancer staging went into effect on Jan. 1, 2014.

The revision by FIGO followed a series of meetings which were concluded in Italy at the end of 2012. Representatives of several international organizations including the SGO participated in these deliberations under the leadership of Professor Lynette Denny from South Africa, the Chair of FIGO committee on Gynecologic Oncology.

The proposed changes were subsequently approved by the FIGO Executive Board, The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC). **This new staging also applies to fallopian tube cancer and primary peritoneal cancer (where feasible). To keep the summary simple, we will just refer to ovary.**

**The new staging is summarized in this FIGO Ovarian Cancer Staging document with changes in italics. The guidelines will be published in the January 2014 issue of the *International Journal of Gynecology and Obstetrics*.**

[https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging\\_1.10.14.pdf](https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf)

請依據 2014 年新版 FIGO Ovarian Cancer Staging 詳實記載 FIGO 病理期別。

<https://cancerstaging.org/About/news/Pages/New-FIGO-Rules-to-be-Included-in-Next-Edition-of-AJCC-Staging-System.aspx>

## **New FIGO Rules to be Included in Next Edition of AJCC Staging System**

The International Federation of Obstetricians and Gynecologists (FIGO) has developed new staging rules for **ovarian, fallopian tube and primary peritoneal cancers**.

These new cancer staging rules will be incorporated into the **8th Edition of the AJCC Cancer Staging System**.

Until the release of the AJCC Cancer Staging System, all nationally collected US cancer statistics data for ovarian, fallopian tube, and primary peritoneal cancers **must be based on the current AJCC Cancer Staging Manual (7th Edition)**.

**AJCC 聲明: 卵巢癌新版 FIGO staging 將納入 AJCC 第八版中修訂; 直至出版 AJCC 第八版之前, Ovary and Primary Peritoneal Carcinoma TNM staging 依舊使用 AJCC 第七版登錄。**

附件二

癌症登記「泌尿系統多發癌症」申報原則，修訂如下：

Table 1 – Urothelial Tumors

Urothelial/Transitional Cell Tumors	M code	Urothelial/Transitional Cell Tumors	M code
With squamous differentiation	8120	Papillary carcinoma, NOS	<b>8050</b>
With glandular differentiation		Papillary transitional cell	<b>8130</b>
With trophoblastic differentiation		Micropapillary	8131
Nested		Lymphoepithelioma-like	8082
Microcystic		Plasmacytoid	
Transitional cell, NOS		Giant cell	8031
Sarcomatoid	8122	Undifferentiated	8020

Urinary MP

Renal Pelvis, Ureter, Bladder, and Other Urinary Multiple Primary Rules – Matrix  
C659, C669, C670-C679, C680-C689  
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Rule	Site	Histology	Timing	Behavior	Notes/Examples	Primary
M6	Bladder	Any combination of: • Papillary carcinoma (8050) or • Transitional cell carcinoma (8120-8124) or • Papillary transitional cell carcinoma (8130-8131)				Single*
M7			More than three (3) years apart			Multiple**
M8	Two or more of the following sites • Renal pelvis (C659) • Ureter(C669) • Bladder (C670-C679) • Urethra /prostatic urethra (C680)	Urothelial tumors (See Table 1)*				<del>Single*</del> <b>Multiple</b>
M9		Tumors with histology codes different at the first (xxxx), second (xxxx), or third (xxx) number				Multiple**
M10	Tumors with topography codes different at the second (Cxxx) and/or third (Cxx) character					Multiple**
M11	Does not meet any of the above criteria				When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.	Single*

註解：僅修正 Table 1 & M8 規則，其餘規則不變。